Documentation. [[CoreRx:Organization]] shall keep complete, accurate and authentic accounts, notes, data and records of the Services performed under this Agreement adequate to comply with all applicable laws, rules and regulations. Without limiting the generality of the foregoing, [[CoreRx:Organization]] shall be responsible for establishing and maintaining the Master Batch Record pertaining to the manufacture of the Products in accordance with applicable law and regulations, and [[CoreRx:Organization]] shall maintain complete and adequate records pertaining to the methods and facilities used by it for the manufacture, processing, testing, packing, labeling, holding and distribution of Products as necessary to permit the Product to be used in humans. Designated representatives of Client shall, upon reasonable notice to [[CoreRx:Organization]], have access to and shall be permitted to review all such records. Upon Client’s written request, [[CoreRx:Organization]] shall supply Client with copies of such records, including its Master Batch Records, for the purposes of assuring product quality and compliance with cGMPs. Except as otherwise specified in a Work Order, following expiration or termination of this Agreement, [[CoreRx:Organization]] shall # continue to make all such records available to Client for a period of five (5) years from the date of such expiration or termination or # upon Client’s written request, transfer such records to Client. After expiration of such retention period, [[CoreRx:Organization]] shall either transfer such records to Client or destroy such records, as determined by Client in its sole discretion. This Section 4.4 is subject to any provision of a Work Order providing for [[CoreRx:Organization]] to deliver any such records to Client. SOPs are excluded as per [[CoreRx:Organization]]’s internal guidelines. SOPs may be reviewed by Client at the [[CoreRx:Organization]]’s location.

Each Loan Party agrees to be bound by the terms of the Lender's application and agreement for letters of credit and the Lender's written regulations and customary practices relating to letters of credit, though such interpretation may be different from such Loan Party's own. In the event of a conflict between such application or agreement and this Agreement, this Agreement shall govern. It is understood and agreed that, except in the case of gross negligence or willful misconduct, the Lender shall not be liable for any error, negligence and/or mistakes, whether of omission or commission, in following any Loan Party's instructions or those contained in the Letters of Credit or any modifications, amendments or supplements thereto.

Documentation. The Award Agreement for a given Award, the Plan and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements.

Documentation. Builder shall advise Owner of, and deliver the original documentation for, any manufacturer's warranties applicable to equipment or Materials furnished by Builder or its Subcontractors or Suppliers.

Documentation. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan.

Documentation. The Administrative Agent’s receipt of the following, each of which shall be originals, telecopies or copies sent by electronic transmission (followed promptly by originals) unless otherwise specified, each properly executed by a Responsible Officer of the Borrower (where applicable), each dated the Effective Date (or, in the case of certificates of governmental officials, a recent date before the Effective Date) and each in form and substance satisfactory to the Administrative Agent and each of the Lenders:

Documentation. Without limiting the generality of the foregoing, if any Borrower is a U.S. Person,

Pharma Co. X marketing personnel representing each of its three ERO brands attended the September 1, 2015 presentation. The presentation included a pitch deck in which PRACTICE FUSION proposed the CDS program focus on the treatment of pain by: “Leverag[ing] Practice Fusion Platform to deliver Clinical Decision Support and measure the impact and real world outcomes on patient care”; delivering “clinical patient-centric provider messages” targeted at healthcare providers with “opioid naive patients with chronic pain,” and with patients currently

Pharma Co. X employees understood based on the presentation that the Pain CDS would keep pain top of mind and influence physicians to switch more patients from non-opioids and IROs to Pharma Co. X’s EROs. Marketing personnel within Pharma Co. X also liked that the proposed Pain CDS allowed Pharma Co. X to, in essence, be present in the exam room while they interacted with patients.

Pharma Co. X Employee #1 and PRACTICE FUSION personnel—including Employee #4 and Employee #5—worked together to design the Pain CDS alert. Employee #5 and Pharma Co. X Employee #1 reviewed the draft Pain CDS from PRACTICE FUSION’S clinical personnel and proposed edits that would enhance the likelihood that the Pain CDS would increase prescriptions.